Birdshot Chorioretinitis

Birdshot chorioretinitis is a rare, long-lasting (chronic) inflammation inside both eyes. It mainly affects the back of the eye: the choroid (the blood-vessel layer under the retina) and the retina (the light-sensing tissue). Doctors also call it birdshot uveitis because it belongs to the uveitis group of diseases. It gets its name from the many small, pale cream spots doctors can see when they look at the retina with a bright light after dilating the pupils; these spots are scattered in a way that reminded early doctors of a birdshot pattern. The disease is strongly linked to a tissue-type marker called HLA-A29; most patients have this marker, which helps doctors recognize the condition. It usually starts in middle age and affects both eyes. Without proper monitoring and treatment, birdshot can slowly harm the retina and reduce vision over time. BioMed Central+2NCBI+2

Birdshot chorioretinitis is a rare, long-lasting eye inflammation that mainly affects the choroid and retina in both eyes. Doctors see many pale “birdshot” spots at the back of the eye, night vision and color vision often get worse, and people can develop floaters, blurred vision, and light sensitivity. It is strongly linked to the HLA-A29 gene and is classified as a non-infectious posterior uveitis. Without treatment, repeated inflammation can damage the retina and the optic nerve and reduce vision. The goal of care is to quiet inflammation fast, prevent flares, and protect vision over years using steroids, steroid-sparing immunosuppressants, and—when needed—biologic drugs or local steroid implants. Orpha+2NCBI+2

---

Other names

Doctors and books may use different names for the same disease. These are common synonyms:

• Birdshot retinochoroidopathy

• Birdshot chorioretinopathy

• Birdshot uveitis

• Vitiliginous chorioretinitis (older term)
  All of these refer to the same clinical entity characterized by bilateral posterior uveitis with cream-colored choroidal lesions and a close association with HLA-A29. EyeWiki+1

---

Types

Birdshot does not have strict “subtypes” like some other eye diseases, but doctors still describe patterns or stages that help with diagnosis and follow-up:

1. Early/active inflammatory phase.
   In the early course, people may have vitreous cells (vitritis) and leakage from retinal vessels even before the classic cream spots are obvious. Symptoms are often vague (blur, floaters, glare). EyeWiki

2. Lesion-dominant phase.
   Over time, the oval, cream choroidal spots become visible around the optic nerve and posterior pole and radiate outward. These lesions reflect inflammation in the choroid. EyeWiki

3. Complication-dominant phase.
   If inflammation persists, people can develop cystoid macular edema, vascular narrowing, retinal pigment changes, and sometimes optic nerve atrophy. These changes are the main reasons vision can decline. EyeWiki

4. HLA-A29–positive typical vs. rare “birdshot-like” presentations.
   The classic form is HLA-A29–positive; a rare birdshot-like picture without HLA-A29 has been reported and may represent a different or overlapping condition. MDPI

5. Imaging-defined patterns.
   On advanced imaging, doctors may describe disease using what each tool highlights—for example, ICG-dominant “dark dots” in the choroid, FAF zones of hypo-autofluorescence, OCT signs of retinal or choroidal thinning, or ERG delay patterns. These are “types” only in the sense of how we see the disease, not different diseases. PMC+3PubMed+3AAO Journal+3

---

Causes

Important note: birdshot is non-infectious and autoimmune-mediated. When we say “causes” here, we mean factors that may drive or contribute to the disease. Scientists have strong evidence for some items (like HLA-A29 and ERAP genes) and developing evidence for others (immune pathways). I’ll say this clearly where relevant.

1. HLA-A29 genetic association (major driver).
   More than 90% of people with birdshot carry HLA-A29, a human leukocyte antigen (tissue type). This marker strongly raises the chance of getting birdshot and guides doctors toward the diagnosis. It is the best-established risk factor. PMC

2. ERAP2 gene variants.
   Variants in ERAP2 (an enzyme that trims proteins for HLA presentation) are strongly linked to birdshot. ERAP2 can change the peptide repertoire presented by HLA-A29, which may trigger autoimmune T-cell responses in the eye. PMC+2PMC+2

3. ERAP1 gene variants.
   Changes in ERAP1 act alongside ERAP2 and HLA-A29 in some people, further shaping the peptides shown to T cells. Together, these findings place birdshot within the “MHC-I-opathy” family of immune diseases. PMC

4. Class I–restricted CD8+ T-cell autoimmunity.
   Because HLA-A29 presents peptides to CD8+ T cells, researchers suspect autoreactive CD8+ cells attack retina/choroid structures after recognizing self-peptides. Studies have detected T cells reactive to retinal proteins in some patients. ScienceDirect

5. Th17/IL-17 pathway activation.
   Many autoimmune diseases show a Th17 signature. In birdshot, Th17 cells and IL-17 have been found at higher levels in patient samples, suggesting a role in sustaining chronic inflammation. PMC+2PubMed+2

6. Tc17 (IL-17–producing CD8+) responses.
   Beyond CD4 Th17 cells, Tc17 CD8+ cells may bridge HLA-A29/ERAP antigen presentation with class I–restricted retinal immune responses, further fueling local inflammation. BioMed Central

7. Middle-age immune shifts.
   The disease often starts at 40–60 years. Immune regulation changes with age may lower tolerance to self-antigens in the eye, allowing chronic inflammation to persist. (Timing pattern described consistently across reviews.) BioMed Central

8. Population ancestry (exposure of risk alleles).
   Birdshot is reported more often in people of Northern/Western European ancestry, likely because HLA-A29 and ERAP risk haplotypes are more common in those populations—not because ancestry itself “causes” inflammation. Nature

9. Abnormal antigen processing in the eye.
   The ERAP–HLA-A29 axis can alter which peptide fragments are displayed to T cells, possibly revealing self-peptides that the immune system mistakenly targets. Frontiers

10. Breakdown of ocular immune privilege.
    The eye usually keeps inflammation down (“immune privilege”). Persistent antigen presentation plus cytokines like IL-17 may overcome this control, letting inflammation take root in the choroid and retina. (Mechanistic concept supported by immune-pathogenesis reviews.) Frontiers

11. Molecular mimicry after infections (hypothesis).
    Some researchers propose that a past infection may prime T cells against foreign peptides that look like retinal peptides, starting an autoimmune chain reaction in HLA-A29 carriers. This is a theory, not a proven cause. EyeWiki

12. Retinal vessel inflammation (vasculitis) as a perpetuator.
    Once inflammation begins, retinal vasculitis can keep immune cells trafficking into the eye, sustaining disease activity and tissue injury over time. (Commonly reported in clinical descriptions.) birdshot.org.uk

13. Local choroidal hypoxia and tissue stress.
    Inflamed choroidal vessels may not feed the retina normally, creating tissue stress that keeps the immune cycle going and contributes to lesion formation seen on imaging. (Inferred from imaging/angiography patterns and reviews.) PubMed

14. Genetic “double dose” of Aw19 family alleles.
    Having two copies of HLA-Aw19 family alleles (which includes HLA-A29) appears to increase risk in carriers, suggesting gene dosage matters. iovs.arvojournals.org

15. Environmental antigens (unknown triggers).
    Because ERAP-HLA pathways present peptides from many sources, non-infectious environmental peptides could act as initial triggers in genetically predisposed people. This remains speculative but is biologically plausible. Frontiers

16. Systemic immune “set point.”
    Studies show differences in circulating T-cell subsets in active vs. inactive disease, implying that each person’s immune set point helps determine whether birdshot starts and how active it becomes. Nature

17. Cytokine networks (IL-23/IL-17 axis).
    The IL-23–IL-17 axis stabilizes Th17/Tc17 responses. Signals along this axis can lock in chronic inflammation in other autoimmune diseases and likely contribute here as well. PMC

18. Autoantigens in retina/choroid (candidate targets).
    Several retinal proteins have been proposed as immune targets. While no single autoantigen explains all cases, their presence supports an autoimmune mechanism. ScienceDirect

19. Ocular barrier disruption.
    Inflammation can weaken the blood-retina barrier, letting more immune cells and proteins enter the retina, which worsens edema and keeps the process going. (Common uveitis mechanism noted in reviews.) PMC

20. Chronicity itself.
    Once established, birdshot tends to be long-lasting. Chronic inflammation promotes more structural change (thinning, scarring), which in turn presents more self-antigen, creating a cycle of persistence. PMC

---

Symptoms

1. Blurred or dim vision.
   People often notice that details look fuzzy, especially under poor lighting. This is due to inflammation affecting the macula and retinal pathways. NCBI

2. Floaters.
   You may see small moving specks or cobwebs. These come from cells and debris in the vitreous gel when inflammation is present. NCBI

3. Night vision problems (nyctalopia).
   Seeing in the dark becomes hard because rod-dominated pathways are affected by inflammation and retinal dysfunction. NCBI

4. Color vision changes (dyschromatopsia).
   Colors may look washed out or “not right,” reflecting cone pathway stress and macular involvement. EyeWiki

5. Glare or light sensitivity.
   Bright light can be uncomfortable, and headlights or sunlight may “bleach out” vision due to macular edema or loss of contrast. EyeWiki

6. Flashes of light (photopsias).
   Brief flashes may appear because inflamed or stressed retinal cells misfire. EyeWiki

7. Reduced contrast sensitivity.
   Shades of gray are harder to separate; faces and text can be harder to recognize in low contrast. NCBI

8. Areas of missing vision (scotomas).
   People may notice small blind patches or a sense that part of the view “falls out,” especially near the center or around the blind spot. Retina Specialist

9. Peripheral field loss or constriction.
   Side vision can narrow over time, reflecting widespread retinal pathway dysfunction. Retina Specialist

10. Worsening vision with disease duration.
    Vision may be fairly good at first but can decline if inflammation remains active for months or years. PMC

11. Seeing straight lines as wavy (metamorphopsia).
    When the macula swells or changes, the grid of lines can look bent or uneven. Orpha

12. Enlarged blind spot.
    Testing often shows a bigger blind spot because inflammation affects tissues around the optic nerve. Patients may sense this as a “gap” near central vision. EyeWiki

13. Difficulty with reading speed.
    Even if letters are legible, processing is slower due to reduced contrast, small scotomas, or macular dysfunction. (Consistent with functional reports in reviews.) PMC

14. Vague “something is wrong” feeling with vision.
    Many people cannot name a single symptom early on; they just feel vision is off, which is why diagnosis is often delayed. EyeWiki

15. Usually little to no eye pain.
    Unlike some other uveitis types, pain and redness are often mild or absent because the front of the eye is not the main site of inflammation. EyeWiki

---

Diagnostic tests

A) Physical examination (in-clinic eye exam)

1. Visual acuity test (letters chart).
   Checks how clearly you see at distance. In birdshot, vision can be normal early and drop later, so acuity alone does not show the whole picture. Review of Ophthalmology

2. Pupil dilation and slit-lamp biomicroscopy.
   After dilating the pupils, the doctor examines the vitreous and retina. Mild vitritis may be present. This exam is how the classic cream lesions are spotted. EyeWiki

3. Dilated fundus examination of lesion pattern.
   Doctors look for multiple, oval, pale choroidal spots around the optic disc and posterior pole, often in both eyes, which is the hallmark of birdshot. EyeWiki

4. Intraocular pressure measurement.
   Pressure is checked because any eye inflammation and its therapies can change pressure; while not diagnostic, it’s part of safe care. (Standard ophthalmic practice referenced in reviews.) PMC

5. Assessment for complications (macular edema, vasculitis).
   On exam and with imaging, clinicians look for macular swelling, vessel leakage, and optic nerve changes that explain symptoms and guide treatment. EyeWiki

B) Manual/functional tests (simple performance tests)

6. Amsler grid.
   A small grid you look at to detect wavy or missing areas in central vision (metamorphopsia, scotomas). Useful for day-to-day monitoring.

7. Color vision testing (e.g., Ishihara).
   Many patients have color desaturation; formal color testing helps document and monitor it. EyeWiki

8. Contrast sensitivity (e.g., Pelli-Robson).
   Important because contrast can fall even when letter acuity looks okay, matching real-world complaints like “words fade” or “faces lack detail.” NCBI

9. Visual field testing (automated perimetry).
   Maps side vision and blind-spot size. Birdshot commonly shows diffuse constriction, paracentral scotomas, or blind-spot enlargement despite decent central acuity. EyeWiki

10. Dark adaptation tests (when available).
    Explain night-vision complaints by measuring how fast the eye adapts to darkness; rods are often affected in birdshot.

C) Laboratory and pathological tests (to support diagnosis and rule out mimics)

11. HLA-A29 testing.
    A strong supportive test; a positive HLA-A29 in the right clinical context makes birdshot much more likely. It is not the only criterion, but it is highly characteristic. EyeWiki

12. Syphilis serology (RPR and confirmatory treponemal test).
    Done to exclude syphilis, which can mimic many forms of posterior uveitis; a positive result excludes birdshot under SUN rules. EyeWiki

13. Tuberculosis screening (PPD or interferon-gamma release assay).
    Used to exclude TB-related uveitis, another important mimic. EyeWiki

14. Sarcoidosis work-up (ACE/lysozyme; chest imaging).
    Sarcoid can copy parts of the birdshot picture; labs and imaging help rule it out. EyeWiki

15. Basic inflammatory labs (CBC, inflammatory markers).
    General labs help detect other systemic causes; they are supportive and help ensure nothing is missed. EyeWiki

Pathology (biopsy) is rarely needed; diagnosis is clinical plus imaging with selective labs to rule out mimics. BioMed Central

D) Electrodiagnostic tests (measure retinal function)

16. Full-field electroretinogram (ERG).
    The ERG records electrical signals from the retina. In birdshot, the 30-Hz cone flicker response is often delayed and is highly sensitive for detecting disease activity and monitoring change over time. PMC+1

17. Multifocal ERG (mfERG).
    Shows local areas of reduced retinal function across the central retina, matching field defects and patient symptoms; helps track macular function. (Supported by ERG literature.) PMC

E) Imaging tests (look at structure and blood flow)

18. Indocyanine green angiography (ICG/ICGA).
    Key test for birdshot. ICGA shows many “hypofluorescent dark dots” in the choroid, often more numerous than the visible spots. This finding appears in nearly all active cases and helps with early diagnosis and monitoring. PubMed+2AAO Journal+2

19. Fluorescein angiography (FA).
    FA highlights retinal vessel leakage and macular edema. It is less sensitive than ICGA for choroidal lesions but remains useful for macular and vascular assessment. ajo.com

20. Optical coherence tomography (OCT and enhanced-depth OCT).
    OCT provides cross-sectional images of the retina and choroid. Doctors use it to detect and follow macular edema, measure retinal thinning, and evaluate choroidal thickness over time. OCT-A can show microvascular flow changes related to birdshot. AAO+1

21. (Bonus for completeness) Fundus autofluorescence (FAF).
    FAF maps retinal pigment epithelium health. Birdshot often shows peripapillary and arcuate hypo-autofluorescence, which correlates with disease burden and chronicity. AAO Journal

22. (Bonus) Wide-field color fundus photography.
    Serial photos document lesion number and pattern over time for objective comparison at follow-up. (Widely used in clinical practice; emphasized in clinical reviews.) AAO

I listed more than 20 individual tests/tools across categories so you can see exactly how each is used in practice; the core set most clinics rely on is dilated exam + visual fields + ICGA/FA + OCT + ERG. AAO+2JAMA Network+2

Non-pharmacological treatments (therapies & others)

(For practicality and readability, I’m giving the most useful, well-supported options first. Several are “adjuncts” that improve comfort, reduce risk, or support vision while medical therapy controls inflammation.)

1) Ultraviolet (UV) and glare protection.
Wearing wraparound sunglasses and a hat reduces light scatter and photophobia while inflamed tissues heal. Blue-blocking and UV-400 filters can make indoor and outdoor light more comfortable and may reduce reflex tearing and squinting. This does not treat the immune disease itself, but it protects the retina and improves function during flares and after dilating drops. Ask your clinician which lens tint works best for you. AAO

2) Mydriatic/cycloplegic comfort drops (as supportive therapy).
Short courses of dilating/relaxing drops (e.g., cycloplegics) are sometimes used to relieve ciliary spasm pain, photophobia, and to prevent iris adhesions in uveitis. They are not disease-modifying but can greatly improve comfort while systemic therapy takes effect. Use only under ophthalmologist guidance. EyeWiki

3) Low-vision rehabilitation.
If contrast sensitivity, color vision, or night vision remain reduced, low-vision specialists can prescribe task lighting, high-contrast reading aids, magnifiers, and digital tools. Early referral preserves independence and safety at home and work while medical therapy continues. guidedogs.org.uk

4) Smoking and vaping cessation.
Smoking is linked to a higher risk of non-infectious uveitis and worse complications like macular edema; emerging data suggest e-cigarettes also raise uveitis risk. Stopping nicotine lowers inflammatory and vascular stress and supports eye health long-term. ScienceDirect+2PMC+2

5) Sleep and stress management.
Stress and inadequate sleep are associated with more frequent uveitis episodes in recurrent disease. Simple steps—regular sleep timing, cognitive-behavioral strategies, and relaxation training—can help reduce triggers while immunosuppression controls the core inflammation. Nature+1

6) Vaccination planning while immunosuppressed.
People on steroid-sparing agents or biologics should follow age-appropriate, inactivated vaccine schedules (e.g., influenza, pneumococcal, COVID-19). Live vaccines are generally avoided during significant immunosuppression; discuss timing with your uveitis and primary teams. Proper vaccination reduces infection-related flares and severe illness. ophthalmology.theclinics.com+1

7) Nutrition for ocular health (adjunct).
A diet rich in leafy greens (lutein/zeaxanthin) and omega-3 fatty acids supports retinal metabolism and macular pigment; while not a cure, this pattern complements medical care and may improve comfort and tear film quality. See the “What to eat” section below. PMC

8) Patient education and peer support.
Specialist guides and patient groups (e.g., Birdshot Uveitis Society) help with practical tips, emotional support, research updates, and navigating long courses of therapy. Staying informed improves adherence and outcomes. birdshot.org.uk+1

9) Regular specialist follow-up and flare plan.
Because BSCR can be quiet even when damage is ongoing, scheduled monitoring (OCT, fields, angiography when needed) and a written flare plan reduce delays in treatment adjustments that protect vision. NCBI

10) Workplace and lighting adaptations.
Task lighting, anti-glare screens, larger fonts, and frequent rest breaks lower visual strain during flares or while adjusting to new prescriptions after treatment. Low-vision professionals can advise. guidedogs.org.uk

(Additional supportive strategies—safe exercise, fall-prevention, and cataract-surgery planning once inflammation is quiet—are often useful individualized add-ons.) Mayo Clinic

---

Drug treatments

Important: No drug is FDA-approved specifically for “birdshot chorioretinitis.” Several are approved for non-infectious intermediate, posterior, or panuveitis and are widely used in BSCR; others are off-label but standard in uveitis care. I note the status in each item.

1) Adalimumab (Humira®) – TNF-α inhibitor (on-label for NIU).
What it does & purpose: A targeted biologic that reduces intra-ocular inflammation and helps prevent relapses; a steroid-sparing mainstay when disease is bilateral/chronic. Dose/time: Adult NIU labeling commonly uses an initial loading followed by 40 mg SC every other week (see label for complete regimen). Mechanism: Neutralizes TNF-α, a key cytokine in ocular inflammation. Side effects: Risk of serious infections, reactivation of TB/hepatitis B, injection-site reactions; rare demyelination or malignancy signals—screen and monitor per label. Evidence: FDA labeling specifically includes non-infectious intermediate, posterior, and panuveitis. FDA Access Data

2) Adalimumab biosimilars (e.g., Hyrimoz®, Amjevita®) – TNF-α inhibitors (on-label for NIU as biosimilars to Humira).
Purpose/mechanism/risks mirror originator adalimumab; dosing follows the biosimilar label. They expand access and can reduce cost; switching considerations should be guided by the treating uveitis specialist. FDA Access Data+1

3) Dexamethasone intravitreal implant (Ozurdex®) – corticosteroid (on-label for NIU posterior segment).
Purpose: A biodegradable implant that releases dexamethasone to rapidly reduce vitreous cells and cystoid macular edema (CME). Dose/time: 0.7 mg intravitreal by specialist; effects often peak over weeks and can be repeated per label and clinical status. Mechanism: Broad anti-inflammatory glucocorticoid action. Side effects: IOP rise and cataract progression are the big ones; infection risk from injection. FDA Access Data+1

4) Fluocinolone acetonide non-bioerodible intravitreal implant (Yutiq® 0.18 mg) – corticosteroid (on-label for chronic NIU posterior segment).
Purpose: A tiny 3-year sustained-release device to reduce recurrence of posterior uveitis and cut steroid burden. Mechanism: Local glucocorticoid release at ~0.25 µg/day. Dose/time: In-office intravitreal insertion. Side effects: Cataract and IOP elevation—often need glaucoma drops and monitoring. Evidence: FDA review showed significant reduction in uveitis recurrence vs. sham at 6 months. FDA Access Data+1

5) Fluocinolone acetonide surgical implant (Retisert® 0.59 mg) – corticosteroid (on-label for chronic NIU posterior segment).
Purpose: A surgically sutured implant releasing steroid over ~2–3 years for severe, recurrent disease. Mechanism: Local sustained glucocorticoid. Risks: High rates of cataract surgery and glaucoma surgery over time—used when benefits outweigh risks. FDA Access Data+1

6) Systemic corticosteroids (e.g., oral prednisone).
Purpose: Fast inflammation control during flares or as bridge to steroid-sparing therapy. Dose/time: Shorter high-dose tapers, then ≤5–10 mg/day maintenance only if absolutely necessary, due to systemic toxicity. Mechanism: Broad immune suppression. Risks: Glucose intolerance, hypertension, osteoporosis, infection; ophthalmic cataract/IOP issues. Evidence in BSCR: Cohorts show many patients can be maintained at low doses after disease control, often combined with steroid-sparing agents. MDPI

7) Mycophenolate mofetil (off-label for BSCR/NIU).
Purpose: A common steroid-sparing oral agent to maintain quiescence. Mechanism: Inhibits inosine monophosphate dehydrogenase → blocks lymphocyte proliferation. Dose/time: Often 1–1.5 g twice daily (specialist adjusts). Risks: Cytopenias, GI upset, teratogenicity, infection risk—lab monitoring needed. Label source for safety/pharmacology: FDA label (transplant indications). NCBI

8) Methotrexate (off-label for BSCR/NIU).
Purpose: Weekly antimetabolite for steroid-sparing disease control. Mechanism: DHFR inhibition and anti-inflammatory adenosine pathway effects. Dose/time: Typically 10–25 mg once weekly with folic acid; lab monitoring. Risks: Hepatotoxicity, cytopenias, stomatitis; avoid in pregnancy. (FDA label supports safety/pharmacology in approved indications.) NCBI

9) Cyclosporine (off-label for BSCR/NIU).
Purpose: Calcineurin inhibitor that can be paired with antimetabolites to maintain quiescence. Mechanism: Blocks T-cell IL-2 transcription. Risks: Hypertension, nephrotoxicity, tremor, gingival hyperplasia—blood-pressure and creatinine checks are mandatory. (Use label for monitoring/risks.) NCBI

10) Tocilizumab (off-label biologic; anti-IL-6).
Purpose: For refractory BSCR, especially treatment-resistant macular edema after anti-TNF. Mechanism: IL-6 receptor blockade. Dose/time: IV or SC per rheumatology protocols. Evidence: Case series and cohort reports show improved vision and macular thickness in refractory birdshot; not FDA-approved for uveitis. Risks: Infection, liver enzyme rise, neutropenia; follow label monitoring. PubMed+2SpringerOpen+2

11) Intravitreal sirolimus (investigational for NIU).
Purpose: mTOR inhibition delivered inside the eye; studied doses show inflammation reduction in NIU-PS trials (DE-109/SAKURA/LUMINA programs), but no U.S. uveitis approval. Use is clinical-trial/investigational. PubMed+2AAO Journal+2

12) Interferon-alpha-2a (off-label; specialist use).
Purpose: A systemic option for severe, refractory non-infectious uveitis in expert centers. Evidence: Classic series demonstrate steroid-sparing control in difficult uveitis; careful monitoring required. Risks: Flu-like symptoms, mood changes, cytopenias. PMC

Notes: Dosing and sequencing are individualized. Always coordinate among uveitis specialist + rheumatology and follow FDA labels for safety screening and monitoring. AAO+1

---

Dietary molecular supplements

Supplements do not replace immunosuppressive therapy. Discuss all products with your clinician to avoid interactions.

1) Omega-3 fatty acids (EPA/DHA).
What & why: Marine omega-3s support retinal cell membranes and have anti-inflammatory effects that may ease ocular surface discomfort and support macular health. Dose commonly used: 1–2 g/day combined EPA+DHA (food-first via oily fish is ideal). Mechanism: Competes with arachidonic acid pathways and generates pro-resolving mediators. PMC

2) Lutein + Zeaxanthin.
What & why: Carotenoids that build macular pigment, improving light filtering and reducing oxidative stress; helpful for glare and contrast. Dose: Often 10 mg lutein + 2 mg zeaxanthin/day (check product). Mechanism: Antioxidants concentrated in the macula. MDPI

3) Vitamin D (when deficient).
What & why: Low vitamin D is associated with higher risk and activity of non-infectious uveitis. Correcting deficiency may help immune balance. Dose: Based on labs (commonly 1000–2000 IU/day or clinician-directed repletion). Mechanism: Modulates innate/adaptive immunity. PubMed

4) Curcumin (turmeric extract; enhanced-bioavailability forms).
What & why: Anti-inflammatory polyphenol with small clinical studies suggesting benefit in uveitis-related symptoms; evidence is preliminary. Dose: Product-dependent; follow standardized formulations. Mechanism: NF-κB/COX-2 modulation; antioxidant. PubMed+1

5) Antioxidant blend for macular health (AREDS2-style pattern).
What & why: Mixtures with vitamins C/E, zinc/copper, plus lutein/zeaxanthin support retinal antioxidant capacity; primarily studied in AMD but often used for retinal support. Mechanism: Reduces oxidative stress burden. MDPI

6) Balanced diet emphasizing leafy greens, colorful veg, fish, nuts.
What & why: Food-first delivery of carotenoids and omega-3s improves overall ocular nutrition and cardiometabolic health that indirectly supports the eye. Mechanism: Antioxidant and anti-inflammatory nutrient pattern. PMC

(Other compounds—resveratrol, quercetin, and specific probiotic strategies—have preclinical signals but limited clinical evidence in uveitis; use only within research or with specialist advice.) PMC

---

Immune-booster/regenerative/stem-cell” drugs

There are no FDA-approved “immune booster” or stem-cell drugs for BSCR or NIU. Below are immune-modulating options sometimes used off-label for refractory disease, and one investigational intraocular drug. Use only with a uveitis expert and proper monitoring.

1) Tocilizumab (anti-IL-6).
Role: For refractory BSCR, especially stubborn macular edema after anti-TNF failure. Mechanism: Blocks IL-6 signaling. Dose: IV or SC per label (off-label for uveitis). Function: Reduces edema/inflammation; steroid-sparing. PubMed+1

2) Interferon-alpha-2a.
Role: Systemic immunomodulator for severe, resistant NIU in expert hands. Mechanism: Modulates immune pathways and antiviral signaling. Function: Can induce remission and reduce steroid needs. PMC

3) Intravitreal sirolimus (DE-109; investigational).
Role: Trial-based therapy for NIU-PS; not FDA-approved. Mechanism: mTOR inhibition reduces T-cell activity. Function: Reduced vitreous haze in higher-dose arms in trials. PubMed

4) Combination antimetabolite + calcineurin inhibitor (e.g., mycophenolate + cyclosporine).
Role: Classic steroid-sparing pairing to keep chronic NIU quiet. Mechanism: Dual blockade of lymphocyte activation and proliferation. Function: Maintains long-term quiescence with careful labs. NCBI

5) Systemic methotrexate (weekly).
Role: Anchor agent for steroid-sparing control; long safety track record with labs and folate. Mechanism: Antimetabolite with anti-inflammatory adenosine effects. NCBI

6) Adalimumab (or biosimilar) rescue/maintenance.
Role: Preferred biologic on-label for NIU; often first-line steroid-sparing in bilateral disease. Mechanism: TNF-α blockade to prevent flares. FDA Access Data+1

---

Surgeries (procedures & why they’re done)

1) Retisert® surgical implantation.
A small fluocinolone device is sutured to the sclera in the operating room to release steroid for years, lowering relapse frequency in severe, chronic disease. It’s chosen when systemic therapy fails or is not tolerated. Risks include cataract and glaucoma requiring surgery. FDA Access Data+1

2) Yutiq® in-office intravitreal implantation.
A tiny fluocinolone implant inserted through a special injector in clinic to reduce posterior uveitis recurrences for up to three years; used when frequent flares occur or systemic therapy is unsuitable. FDA Access Data+1

3) Ozurdex® intravitreal implant.
An in-office dexamethasone implant for rapid control of vitreous cells and CME; helpful as a bridge while systemic therapy is optimized. FDA Access Data

4) Cataract extraction (phacoemulsification with IOL).
Chronic inflammation and steroid use often cause cataracts; surgery after inflammation is quiet restores clarity and can markedly improve vision. Mayo Clinic

5) Glaucoma surgery (trabeculectomy or tube shunt).
If medications and laser cannot control steroid-related or uveitis-related high pressure, surgery protects the optic nerve and preserves vision. Mayo Clinic

---

Preventions

1. Don’t smoke or vape. It raises uveitis risk and complications; quitting helps your eyes and overall health. ScienceDirect+1

2. Sleep enough and manage stress. Poor sleep and stress are linked to more uveitis episodes. Nature

3. Keep vaccines current when immunosuppressed (inactivated vaccines as advised). AAO

4. Protect from bright sun/UV to reduce photophobia and glare discomfort. AAO

5. Follow your medicine plan and labs—early dose tweaks prevent flares. NCBI

6. Healthy eating pattern emphasizing greens, fish, nuts (see below). PMC

7. Avoid unnecessary live vaccines while on significant immunosuppression. ophthalmology.theclinics.com

8. Report new floaters, flashes, or vision drop early. Fast care protects vision. AAO

9. Eye-safe work and lighting setup to reduce strain during flares. guidedogs.org.uk

10. Join a support community (e.g., Birdshot Uveitis Society) for practical tips and updates. birdshot.org.uk

---

When to see a doctor (now vs. routine)

• Immediately if you notice sudden blur, new floaters, flashes, a dark curtain, severe pain, or halos with headache—these may mean active uveitis, CME, retinal problems, or steroid-related high pressure. Don’t wait. AAO

• Promptly for persistent light sensitivity, color washout, night-vision decline, or visual field changes, which can signal smoldering inflammation in BSCR. NCBI

• Routinely as scheduled for OCT/field testing even if you feel fine—BSCR can be active with few symptoms early on. NCBI

---

What to eat and “what to avoid

Eat more of:

• Dark leafy greens (kale, spinach) for lutein/zeaxanthin that support macular pigment. MDPI

• Fatty fish (salmon, sardine, mackerel) for omega-3s supporting retinal membranes. PMC

• Colorful vegetables & fruits (peppers, broccoli, citrus, berries) for antioxidants that combat oxidative stress. PMC

• Nuts and seeds (walnut, almond, flax) for healthy fats and vitamin E. PMC

• Adequate vitamin D (diet and safe sun; supplements only if low, per labs). PubMed

Limit/avoid:

• Tobacco and vaping (raise ocular inflammatory risk). ScienceDirect+1

• Ultra-processed, high-sugar foods that may worsen systemic inflammation and weight-related risks. (General ocular-nutrition consensus.) PMC

• Excess alcohol, which can disturb sleep and interact with medications. Mayo Clinic

• Unverified “immune boosters.” Some herbs interact with immunosuppressants—clear all supplements with your clinician. NCBI

• Live-culture supplements without medical advice if you’re significantly immunosuppressed. ophthalmology.theclinics.com

---

Frequently Asked Questions

1) Is birdshot chorioretinitis curable?
There’s no permanent cure yet, but long-term remission is common with modern systemic therapy and/or local steroid implants. The aim is to keep the eye quiet and protect retinal function. PMC

2) Do I need treatment if my vision seems okay?
Yes—BSCR can quietly damage retinal cells and the optic nerve. Proactive treatment prevents irreversible loss. NCBI

3) What’s first-line therapy?
Often systemic corticosteroids for quick control, then a steroid-sparing agent (e.g., mycophenolate, methotrexate) or adalimumab (on-label for NIU) to maintain quiescence. FDA Access Data+1

4) When are eye implants considered?
When disease keeps relapsing, systemic drugs aren’t tolerated, or macular edema recurs, Ozurdex/Yutiq/Retisert can reduce relapses and edema. Choice depends on duration needed and risk of IOP/cataract. FDA Access Data+1

5) How often will I be seen?
Early on, visits are frequent (weeks) with OCT and sometimes angiography; once stable, intervals can lengthen, but regular monitoring is essential. NCBI

6) Can I drive?
If visual acuity, peripheral fields, glare tolerance, and night vision meet your local legal standards. Low-vision aids and antiglare lenses help. Your doctor will advise. guidedogs.org.uk

7) Are biologics safe?
They are effective but increase infection risk; proper screening, vaccinations, and monitoring make them safer. Decisions are individualized. FDA Access Data+1

8) Will I get cataracts or glaucoma?
Steroids (local or systemic) can speed cataract and raise eye pressure; careful dosing, monitoring, and, if needed, surgery manage these risks. FDA Access Data+1

9) Does diet matter?
Diet doesn’t replace treatment, but omega-3s and carotenoids support retinal health. Correct vitamin D deficiency if present. PMC+2MDPI+2

10) Are there stem-cell cures?
No approved stem-cell therapies for BSCR/NIU. Some intraocular sirolimus and other approaches are in trials, but not standard care. PubMed

11) Can stress trigger flares?
Studies in recurrent uveitis link stress and poor sleep to more episodes; practical stress-reduction can help alongside medical therapy. Nature

12) Is BSCR genetic?
Most patients carry HLA-A29, but BSCR is not simply inherited; relatives rarely develop it. Orpha

13) What about pregnancy?
Plan pregnancy with your uveitis/rheumatology team; some drugs are unsafe and must be changed well in advance. NCBI

14) Can I exercise?
Yes—generally safe and beneficial; avoid high-impact activities during acute flares if vision is unstable. Mayo Clinic

15) Where can I learn more and connect with others?
See Birdshot Uveitis Society and Ocular Immunology & Uveitis Foundation for reliable patient guides and support. birdshot.org.uk+1

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 27, 2025.